Monitoring Patients

In our cohort, we routinely measure:

A full blood count – to detect polycythaemia

A renal profile – to detect early strain on the renal system or early CKD

Liver function tests – to detect early liver inflammation or liver damage

Thyroid function tests – if patients have used thyroid hormones in abuse

A lipid panel – to ascertain if lipid dysfunction is occurring with use.  Particularly suppressed LDL

An ECG – to monitor for cardiac hypertrophy changes

We recommend these are done a minimum of 6 monthly.  Ideally 3 monthly in very high risk users, eg, those not taking a break from use or having high risk behaviour, multiple IPEDS, especially multiple forms or AAS

All patients with ECG changes should be referred for echocardiography or cardiology assessment



This website uses cookies to ensure you get the best experience, please accept these so we can deliver a more reliable service.

Manage preferences